With COVID-19 vaccinations stalling, a new antibody combination treatment by Eli Lilly has shown positive Phase III data of more than 1,000 high-risk patients with COVID.

The combination of bamlanivimab-etesevimab produced a 70% reduction in the risk of patients with COVID-19 being hospitalized or dying. Eleven patients who received the antibody combination were hospitalized but none died. Compared to the placebo patients where 26 were hospitalizations and 10 died.

Click here to read the entire article.